Ciprofloxacin

Generic Name: Ciprofloxacin

Brand Names: Cetraxal, Ciloxan, Cipro, Cipro HC, Ciprodex, Ciprofloxacin, Otiprio, Otixal, Otovel, Proquin

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈FN_₃O_₃

CAS Number: 85721-33-1

Unique Ingredient Identifier: 5E8K9I0O4U

Background: Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.

The first ciprofloxacin containing product was FDA approved on 22 October 1987.

Indication: Ciprofloxacin is only indicated in infections caused by susceptible bacteria.

Ciprofloxacin immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.

A ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa. Ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa. A ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis externa.

A ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitis. A ciprofloxacin eye ointment is indicated for bacterial conjunctivitis.

A ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.

Associated Conditions: Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis, Acute Otitis Externa, Acute Otitis Externa caused by Pseudomonas Aeruginosa, Acute Otitis Media (AOM), Acute Sinusitis, Acute Uncomplicated Pyelonephritis, Bone and Joint Infections, Chronic Otitis Media, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Conjunctivitis caused by Haemophilus influenzae, Conjunctivitis caused by Staphylococcus epidermidis, Corneal Ulcers caused by Serratia marcescens, Corneal Ulcers caused by Staphylococcus aureus, Corneal Ulcers caused by Staphylococcus epidermidis, Corneal Ulcers caused by Streptococcus Pneumoniae, Corneal Ulcers caused by Streptococcus Viridans Group, Corneal Ulcers caused by pseudomonas aeruginosa, Escherichia urinary tract infection, External ear infection NOS, Febrile Neutropenia, Infection of the outer ear caused by susceptible bacteria, Infectious diarrhea, Inhalational Anthrax, Lower respiratory tract infection caused by Enterobacter cloacae, Lower respiratory tract infection caused by Escherichia coli, Lower respiratory tract infection caused by Haemophilus influenzae, Lower respiratory tract infection caused by Haemophilus parainfluenzae, Lower respiratory tract infection caused by Klebsiella pneumoniae, Lower respiratory tract infection caused by Proteus mirabilis, Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae, Nosocomial Pneumonia, Otitis Media (OM), Otitis Media, Purulent, Plague caused by Yersinia pestis, Skin Infections, Typhoid fever caused by Salmonella typhi, UTI caused by Citrobacter diversus, UTI caused by Citrobacter frendii, UTI caused by Entercococcus faecalis, UTI caused by Enterobacter cloacae, UTI caused by Klebsiella pneumoniae, UTI caused by Morganella morganii, UTI caused by Proteus mirabilis, UTI caused by Providencia rettgeri, UTI caused by Pseudomonas aeruginosa, UTI caused by Serratia marcescens, UTI caused by methicillin-susceptible Staphylococcus epidermidis, Uncomplicated Urinary Tract Infections, Acute otitis externa caused by Staphylococcus aureus, Acute, uncomplicated Cystitis caused by Escherichia coli, Acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus, Chronic Prostatitis caused by Escherichia coli, Chronic Prostatitis caused by Proteus mirabilis, Complicated Pyelonephritis caused by Escherichia coli, Complicated Urinary Tract Infection caused by Escherichia Coli, Uncomplicated Gonorrhea caused by Neisseria gonorrhoeae

Clinical Trials

Antibiotic Prophylaxis for Bladder Botox

Phase 4

Recruiting

Conditions: Postoperative Urinary Tract Infection
Idiopathic Overactive Bladder

Interventions: Drug: Ciprofloxacin
Other: Placebo Pill

First Posted Date: 2020-06-23

Last Posted Date: 2025-02-20

Lead Sponsor: University of Alberta

Target Recruit Count: 202

Registration Number: NCT04444440

Locations: 🇨🇦
Urogynecology Clinic - Royal Alexandra Hospital, Edmonton, Alberta, Canada

Efficacy of Ciprofloxacin Therapy in Avoidance of Sepsis in Patient Undergoing Percutanous Nephrolithotomy

Not Applicable

Conditions: Nephrolithiasis

Interventions: Drug: Ciprofloxacin
Drug: Levofloxacin

First Posted Date: 2020-05-05

Last Posted Date: 2021-03-03

Lead Sponsor: Diaa Eldin Taha Ramadan Mohamed

Target Recruit Count: 200

Registration Number: NCT04374188

Locations: 🇪🇬
Kafrelsheikh faculty of medicine, Kafr Ash Shaykh, Kafrelsheikh, Egypt

Evaluation of Treatment Option for Demodicosis in Patients Undergoing Cataract Surgery

Phase 2

Completed

Conditions: Demodex Infestation
Demodicosis
Cataract

Interventions: Drug: Ciprofloxacin Ophthalmic Ointment 0.3%
Other: Tea Tree Oil Shampoo
Other: Baby shampoo
Other: Blephaclean

First Posted Date: 2019-12-19

Last Posted Date: 2020-04-27

Lead Sponsor: Hospital de La Luz

Target Recruit Count: 160

Registration Number: NCT04204954

Locations: 🇲🇽
Hospital de la Luz, Mexico City, Mexico

Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 730357
Drug: Placebo to match BI 730357
Drug: Ciprofloxacin

First Posted Date: 2019-11-01

Last Posted Date: 2023-07-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 85

Registration Number: NCT04147260

Locations: 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States

Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague

Phase 3

Completed

Conditions: Plague, Pneumonic
Plague, Bubonic

Interventions: Drug: Ciprofloxacin
Drug: Streptomycin
Drug: Gentamicin

First Posted Date: 2019-10-01

Last Posted Date: 2025-03-06

Lead Sponsor: University of Oxford

Target Recruit Count: 222

Registration Number: NCT04110340

Locations: 🇲🇬
Professor Mamy Randria, Antananarivo, Madagascar

Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study

Phase 2

Completed

Conditions: Anthrax

Interventions: Drug: Doxycycline 100Mg Tablet
Drug: Ciprofloxacin 500Mg Tablet
Biological: AV7909

First Posted Date: 2019-08-26

Last Posted Date: 2024-03-21

Lead Sponsor: Emergent BioSolutions

Target Recruit Count: 210

Registration Number: NCT04067011

Locations: 🇺🇸
Meridian Clinical Research, LLC, Omaha, Nebraska, United States
🇺🇸
Avail Clinical Research, LLC, DeLand, Florida, United States
🇺🇸
The Center for Pharmaceutical Research, Kansas City, Missouri, United States

and more 1 locations